TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22377484
Drug: Strict glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strict glucose control based on insulin (I-group; n=21)
Study: 22377484
Drug: Strict glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strict glucose control based on oral agents (O-group; n=18)
Study: 17209215
Drug: Multivitamin-multimineral supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multivitamin-multimineral supplement with vitamin C, vitamin E, beta-carotene, and zinc (with cupric oxide)
Study: 17209215
Drug: Additional nutrients
Normalized name: chromous chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Additional nutrients as dietary supplements
Study: 11134690
Drug: 400-mg caplets
Normalized name: guaifenesin
DrugBank: Guaifenesin (DB00874)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 400-mg caplets of Garcinia cambogia (total dose of 2.4 g/day, 1.2 g/day HCA)
Study: 30630862
Drug: Azacitidine maintenance
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Azacitidine maintenance (50 mg/m2, subcutaneously, days 1‐5, every 4 weeks) until relapse, for a maximum of 12 cycles (N = 56)
Study: 28829514
Drug: Somatostatin retained
Normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Somatostatin retained enema, conducted twice every day for at least 30 minutes each time, with treatment courses lasting 7 days.
Study: 28829514
Drug: Basic treatment
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic treatment plan (Control group).
Study: 21302138
Drug: Rabeprazole 5
Normalized name: RABEprazole 5 mg oral delayed release capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabeprazole 5 mg/day
Study: 19703730
Drug: Topical ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical ketamine (10% cream) applied to the symptomatic limb
Study: 17983368
Drug: Polyethylene glycol
Normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyethylene glycol plus bisacodyl tablets
Study: 11725734
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (transcervical Foley balloon + intravaginal misoprostol)
Study: 3126515
Drug: Ethanol (0.695
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol (0.695 g/kg of body weight over a 15‐min period)
Study: 31586424
Drug: Caspofungin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caspofungin (2 mg/kg once daily)
Study: 31586424
Drug: Amphotericin B
Normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amphotericin B deoxycholate (1 mg/kg)
Study: 22946775
Drug: i-Gel(TM)
Normalized name: IOBENGUANE I 123
Approvals — FDA: no, EMA: no, PMDA: no
Description: i-Gel(TM)
Study: 21191437
Drug: Web-based LFQ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Web-based LFQ administration
Study: 21191437
Drug: Interactive voice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interactive voice response system (IVRS)-based LFQ administration
Study: 21191437
Drug: Interviewer-based LFQ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interviewer-based LFQ administration
Study: 21191437
Drug: Paper-based LFQ
Normalized name: paper birch pollen extract
DrugBank: Betula papyrifera pollen (DB10831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paper-based LFQ administration
Study: 33053
Drug: Terfenadine 60,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terfenadine 60, 120 and 240 mg
Study: 26303801
Drug: Elbasvir (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elbasvir (5 to 50 mg for genotype 1; 10 to 100 mg for genotype 3) once daily for 5 days
Study: 14742331
Drug: Caudal ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caudal ketamine group (bupivacaine + S(+)-ketamine 0.5 mg x kg(‐1))
Study: 14742331
Drug: i.v. ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. ketamine group (bupivacaine + S(+)-ketamine 0.5 mg x kg(‐1) i.v.)
Study: 14742331
Drug: Bupivacaine group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine group (plain bupivacaine 0.25% 1 ml x kg(‐1))
Study: 3884688
Drug: 100 mcg
Normalized name: Levo-T 100 MCG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mcg of albuterol powder
Study: 3884688
Drug: 200 mcg
Normalized name: CrM 200 MCG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mcg of albuterol powder
Study: 3884688
Drug: 400 mcg
Normalized name: Biotin 400 MCG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mcg of albuterol powder
Study: 28286262
Drug: IV magnesium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV magnesium sulfate (100 mg/kg)
Study: 11117082
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of right‐to‐left chamber disproportion with CNS, NSF, HB and PY
Study: 8645387
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate (1 mg/kg/day in three divided doses)
Study: 1464342
Drug: Ubiquinone (coenzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ubiquinone (coenzyme Q10) 3 x 33.3 mg/day orally for 4 months
Study: 2982622
Drug: 1 g/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g/m2 of cyclophosphamide pretreatment before chemotherapy
Study: 2982622
Drug: Standard chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard chemotherapy (cyclophosphamide, vincristine, and methotrexate) without pretreatment
Study: 27575409
Drug: Intravitreal ranibizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal ranibizumab monotherapy (IVM)
Study: 27575409
Drug: Intravitreal combination
Normalized name: Dexamethasone Intravitreal Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal combination (IVC) of dexamethasone implant and ranibizumab
Study: 26226350
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of nicotine and moclobemide
Study: 24183037
Drug: Aspirin plus
Normalized name: Aspirin Plus Antacid Extra Strength
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin plus clopidogrel (75 mg clopidogrel + 100 mg aspirin daily)
Study: 24183037
Drug: Aspirin alone
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin alone (100 mg daily)
Study: 12584669
Drug: Candesartan treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan treatment
Study: 17211970
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg morphine + 120 mg ketorolac + saline solution up to 96 ml with an elastomeric pump i.v.
Study: 10980174
Drug: Ofloxacin 400
Normalized name: ofloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofloxacin 400 mg once daily for 5 days
Study: 10980174
Drug: Ofloxacin therapy
Normalized name: Ofloxacin
DrugBank: Ofloxacin (DB01165)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ofloxacin therapy for 3 days
Study: 10385641
Drug: Ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid (UDCA) treatment for 2 years
Study: 6233547
Drug: Inhaling a
Normalized name: Inhalation Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaling a combined preparation of fenoterol 200 micrograms and ipratropium bromide 80 micrograms (Duovent)
Study: 6233547
Drug: Inhaling a
Normalized name: Inhalation Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaling a similar dose of fenoterol
Study: 12735531
Drug: Leisure therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leisure therapy
Study: 9673264
Drug: Acellular vaccine
Normalized name: PERTUSSIS VACCINE,ACELLULAR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acellular vaccine containing pertussis toxin (PT), filamentous hemagglutinin (FHA), and pertactin (PRN)
Study: 18850516
Drug: Vaginal misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vaginal misoprostol (25 microg initial dose, followed by 50 microg doses at 3-6 hour intervals)
Study: 18850516
Drug: Foley catheter
Normalized name: Bard Foley Catheter 18FR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Foley catheter and oral misoprostol (100 microg at 4-6 hour intervals)
Study: 18850516
Drug: Foley catheter
Normalized name: Bard Foley Catheter 18FR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Foley catheter and oral misoprostol
Study: 18850516
Drug: Vaginal misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vaginal misoprostol and Foley catheter with oral misoprostol
Study: 14763920
Drug: Transdermal oestradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal oestradiol plus CPA (n=12)
Study: 9164314
Drug: Lamivudine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamivudine (150 mg twice a day)
Study: 9164314
Drug: Lamivudine plus
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lamivudine plus Loviride (150 mg twice a day plus 100 mg three times a day)
Study: 7696153
Drug: Automated image
Normalized name: triclosan
DrugBank: Triclosan (DB08604)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Automated image analysis for estrogen receptor (ER) content
Study: 7696153
Drug: Automated image
Normalized name: triclosan
DrugBank: Triclosan (DB08604)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Automated image analysis for progesterone receptor (PR) content
Study: 3427825
Drug: Keyhole limpet
Normalized name: Keyhole limpet hemocyanin
DrugBank: Keyhole limpet hemocyanin (DB05299)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Keyhole limpet haemocyanin (KLH) 2.5 mg
Study: 3427825
Drug: Rabies vaccine
Normalized name: RABIES VACCINE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabies vaccine (RV) 170 micrograms
Study: 3427825
Drug: Rabies vaccine
Normalized name: RABIES VACCINE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabies vaccine (RV) 680 micrograms
Study: 12950410
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg levofloxacin once a day over 10 days
Study: 8091868
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg methotrexate (MTX) per week
Study: 8091868
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg methotrexate (MTX) per week
Study: 2855325
Drug: Sequential chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential chemotherapy using three different drug-combinations
Study: 27665002
Drug: Scattered-site Housing
Normalized name: SOLO SITE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scattered-site Housing First (SHF) with Assertive Community Treatment
Study: 25725780
Drug: TAP block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAP block with 20 ml 0.25 % levobupivacaine (100 mg)
Study: 21483384
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg physostigmine in 250 mL N/S 0.9% (Physo group)
Study: 21483384
Drug: 250 mL
Normalized name: TPN Bag 250 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mL N/S 0.9% placebo (Control group)
Study: 18155759
Drug: Adaper Prompt
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adaper Prompt L‐Pop (PLP)
Study: 15107914
Drug: Non-fluoridated dentifrice
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-fluoridated dentifrice with 20% sucrose solution dripped 10 times a day
Study: 10688723
Drug: Narrow-band UVB
Normalized name: Band-Aid Hurt-Free
Approvals — FDA: no, EMA: no, PMDA: no
Description: Narrow-band UVB phototherapy combined with topical tazarotene 0.05% applied once daily
Study: 10688723
Drug: Narrow-band UVB
Normalized name: Band-Aid Hurt-Free
Approvals — FDA: no, EMA: no, PMDA: no
Description: Narrow-band UVB phototherapy (monotherapy)
Study: 2394301
Drug: Fumaric acid
Normalized name: Fumaric Acid
DrugBank: Fumaric acid (DB01677)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fumaric acid combination (FAC-EC)
Study: 28905478
Drug: Alirocumab 75
Normalized name: alirocumab 75 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alirocumab 75 mg every 2 weeks, with potential increase to 150 mg every 2 weeks at week 12 if LDL cholesterol levels were ≥1.8 mmol/L at week 8.
Study: 25783974
Drug: Everolimus with
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Everolimus with complete calcineurin inhibitor elimination
Study: 20671295
Drug: Intranasal d-amphetamine
Normalized name: amphetamine / dextroamphetamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal d-amphetamine (0, 16, 24, and 32 mg/70 kg)
Study: 20671295
Drug: Oral d-amphetamine
Normalized name: amphetamine / dextroamphetamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral d-amphetamine (equal doses to intranasal)
Study: 10181019
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of outcome information and self-efficacy enhancing information
Study: 7589026
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg controlled-release metoprolol
Study: 21784729
Drug: golimumab 100
Normalized name: golimumab 100 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: golimumab 100 mg plus placebo
Study: 21784729
Drug: golimumab 50
Normalized name: GOLIMUMAB 50MG/0.5ML INJ SYRINGE
Approvals — FDA: no, EMA: no, PMDA: no
Description: golimumab 50 mg plus placebo
Study: 16944674
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of zolpidem (Z)
Study: 15351162
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil introduction with cyclosporine reduction (target trough levels 2-4 microg/ml)
Study: 8441139
Drug: Triamcinolone acetonide
Normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triamcinolone acetonide 60 mg intramuscularly
Study: 21190800
Drug: Melatonin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin treatment (single implants on two occasions in summer, n=1399)
Study: 21190800
Drug: Melatonin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin treatment (n=1399)
Study: 21190800
Drug: Melatonin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin treatment in Herd A (n=1399)
Study: 21190800
Drug: Melatonin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin treatment at 60kg live-weight in Year 1
Study: 21190800
Drug: Melatonin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin treatment in Herd B (n=1399)
Study: 14754784
Drug: Continuous sertraline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous sertraline (50-100 mg/day)
Study: 14754784
Drug: Intermittent sertraline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent sertraline (50-100 mg/day)
Study: 11553257
Drug: Tropisetron 5
Normalized name: tropisetron 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tropisetron 5 mg with metoclopramide 5 mg
Study: 352184
Drug: Metoclopramide 10
Normalized name: metoclopramide 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide 10 mg intravenously
Study: 7946181
Drug: Isradipine monotherapy
Normalized name: Isradipine
DrugBank: Isradipine (DB00270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isradipine monotherapy (4.55 +/- 0.56 mg twice daily)
Study: 7946181
Drug: Isradipine plus
Normalized name: Isradipine
DrugBank: Isradipine (DB00270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isradipine plus bopindolol (7.5 +/- 0.63 mg twice daily and 1.16 +/- 0.12 mg once daily)
Study: 7946181
Drug: Isradipine monotherapy
Normalized name: Isradipine
DrugBank: Isradipine (DB00270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isradipine monotherapy and Isradipine plus bopindolol
Study: 3041824
Drug: Once-daily evening
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily evening doses of controlled-release theophylline (Uniphyl tablets)
Study: 7433519
Drug: Mianserin 30-80
Normalized name: mianserin 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mianserin 30-80 mg daily
Study: 7433519
Drug: Diazepam 15-40
Normalized name: diazepam 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam 15-40 mg daily
Study: 28667408
Drug: Daily administration
Normalized name: Prevpac 30mg-500mg-500mg Daily Administration Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily administration of S-1 at a standard dose of 80 mg/m2/day
Study: 28667408
Drug: Alternate-day administration
Normalized name: Alternaria alternata
DrugBank: Alternaria alternata (DB10424)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternate-day administration of S-1 on 4 days a week
Study: 28667408
Drug: Daily administration
Normalized name: Prevpac 30mg-500mg-500mg Daily Administration Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily administration of S-1
Study: 28667408
Drug: Alternate-day administration
Normalized name: Alternaria alternata
DrugBank: Alternaria alternata (DB10424)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternate-day administration of S-1
Study: 17508038
Drug: Neuroprotective drug
Normalized name: NEUROPROTECTIN D1
DrugBank: AP-001 (DB18511)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neuroprotective drug
Study: 15600246
Drug: Peru-15 (recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peru-15 (recombinant cholera vaccine)
Study: 8109763
Drug: Ondansetron 0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 0.15 mg/kg (maximum = 8 mg)
Study: 3396118
Drug: Fosfomycin 8
Normalized name: FOSFOMYCIN
DrugBank: Fosfomycin (DB00828)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fosfomycin 8 g b.i.d.
Study: 3396118
Drug: Ampicillin 2
Normalized name: ampicillin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ampicillin 2 g t.i.d.
Study: 5781487
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C supplementation (40 to 80 mg daily for 17 months)
Study: 5781487
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C supplementation (40 to 80 mg daily for 9 months)
Study: 22804755
Drug: Melatonin 10
Normalized name: melatonin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin 10 mg/day for 28 days
Study: 21709648
Drug: Modified triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified triple loop corrector (appliance therapy)
Study: 21709648
Drug: Positive reinforcement
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Positive reinforcement (reward therapy)
Study: 18651343
Drug: Venlafaxine 37.5
Normalized name: venlafaxine 37.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine 37.5 mg b.i.d. for 7 days followed by 75 mg b.i.d. for another 7 days
Study: 17961403
Drug: Fixed dosage
Normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed dosage of ICS (fluticasone) plus LABA (salmeterol) maintained for 18 months in group A
Study: 17961403
Drug: Tailored dosage
Normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tailored dosage or withdrawal of therapy according to clinical control in group B
Study: 17961403
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy with ICS plus LABA
Study: 17961403
Drug: Adjustment of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjustment of therapy based on clinical parameters in group B
Study: 17961403
Drug: PC(35) sGaw
Approvals — FDA: no, EMA: no, PMDA: no
Description: PC(35) sGaw monitoring in therapy adjustment
Study: 15336593
Drug: HRT group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRT group (n = 146) received a sequential combination of 2 mg estradiol valerate and 1 mg cyproterone acetate and calcium lactate, 500 mg/day (equal to 93 mg Ca2+) alone or in combination with vitamin D3, 100‐300 IU/day.
Study: 15336593
Drug: non-HRT group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: non-HRT group (n = 170) received calcium lactate, 500 mg alone or in combination with vitamin D3, 100‐300 IU/day.
Study: 2455148
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg nifedipine tablet
Study: 2455148
Drug: 2 X
Normalized name: anti-HER2 x HER2 ADC
DrugBank: Zanidatamab zovodotin (DB15472)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 X 10 mg nifedipine capsules
Study: 28739794
Drug: AZD-5847 (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD-5847 (500 mg once daily)
Study: 28739794
Drug: AZD-5847 (1,200
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD-5847 (1,200 mg once daily)
Study: 28739794
Drug: AZD-5847 (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD-5847 (500 mg twice daily)
Study: 28739794
Drug: AZD-5847 (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD-5847 (800 mg twice daily)
Study: 26276704
Drug: Standard Family-Based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Family-Based Treatment (FBT)
Study: 23695207
Drug: Low-fat vegan
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-fat vegan diet with weekly group support and work cafeteria options for 18 weeks
Study: 21145112
Drug: Guided self-help
Normalized name: loratadine
DrugBank: Loratadine (DB00455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Guided self-help (Problem Solving Treatment and exposure) for 6 weeks
Study: 10889113
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy (14.4 Gy, 1.8 Gy per day, five fractions per week)
Study: 8769361
Drug: DHEA 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEA 40 mg sublingually twice daily for 8 weeks
Study: 1555628
Drug: i.v. infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. infusion of 1.5 MU of streptokinase
Study: 4002782
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg muzolimine
Study: 4002782
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg hydrochlorothiazide/50 mg triamterene